Search results for "Neoplastic"

showing 10 items of 2901 documents

Electrochemotherapy for advanced cutaneous angiosarcoma: A European register-based cohort study from the International Network for Sharing Practices …

2019

Abstract Background Cutaneous angiosarcoma (cAS) is a highly aggressive malignancy that challenges the radicality of surgical treatment. Electrochemotherapy (ECT), a skin-directed treatment based on cytotoxic chemotherapy combined with local electric pulses, may be an intraoperative adjunct and a new opportunity in the therapeutic strategy. This cohort study reports the experience with ECT as an option. Methods Data on patients with locally-advanced/metastatic cAS who underwent ECT between October 2013 and October 2018 at eight European centres were prospectively submitted to the InspECT (International network for sharing practices of ECT) register. Patients received therapy according to th…

Register basedmedicine.medical_specialtyElectrochemotherapySkin NeoplasmsElectrochemotherapyHemangiosarcomaSkin metastasesTumour controlPainKaplan-Meier EstimateMalignancyCutaneous angiosarcomaCohort Studies03 medical and health sciencesBleomycin0302 clinical medicineAntibioticsSkin Ulcermedicine80 and overHumansAngiosarcomaCutaneous angiosarcoma; Electrochemotherapy; Skin metastases; Skin-directed therapies; Tumour control; Aged; Aged 80 and over; Antibiotics Antineoplastic; Bleomycin; Cohort Studies; Electrochemotherapy; Feasibility Studies; Female; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Middle Aged; Pain; Patient Reported Outcome Measures; Prospective Studies; Registries; Skin Neoplasms; Skin Ulcer; Treatment OutcomePatient Reported Outcome MeasuresProspective StudiesRegistriesSkin-directed therapiesAgedAged 80 and overInternational networkAntibiotics Antineoplasticbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseAntineoplasticmedicine.anatomical_structureTreatment OutcomeTolerability030220 oncology & carcinogenesisScalpFeasibility Studies030211 gastroenterology & hepatologySurgeryFemaleRadiologybusinessCohort studyInternational journal of surgery (London, England)
researchProduct

The actual management of colorectal liver metastases

2020

Colorectal cancer is one of the most frequent cancers in the world and between 50% and 60% of patients will develop colorectal liver metastases (CRLM) during the disease. There have been great improvements in the management of CRLM during the last decades. The combination of modern chemotherapeutic and biological systemic treatments with aggressive surgical resection strategies is currently the base for the treatment of patients considered unresectable until few years ago. Furthermore, several new treatments for the local control of CRLM have been developed and are now part of the arsenal of multidisciplinary teams for the treatment of these complex patients. The aim of this review was to s…

ReoperationSurgical resectionmedicine.medical_specialtyOrganoplatinum CompoundsColorectal cancerLeucovorinDisease030230 surgery03 medical and health sciencesHepatic Artery0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsHepatectomyHumansInfusions Intra-ArterialMedicineMicrowavesRadiofrequency Ablationbusiness.industryGeneral surgeryLiver NeoplasmsMargins of ExcisionPrognosismedicine.diseaseLiver TransplantationElectroporation030220 oncology & carcinogenesisCamptothecinSurgeryFluorouracilColorectal NeoplasmsbusinessMinerva Chirurgica
researchProduct

Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper

2015

While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational decision making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and combine all the available evidence should be refined, and the Bayesian logic can be instrumental to this end. Likewise, Bayesian-design trials may help optimize the low number of patients liable to be enrolled in …

Research designPathologyData baseResearch methodologyElectronic medical recordDiseaseReviewProceduresTreatment responseClinical trials; Rare cancers; Research methodology; Clinical Studies as Topic; Humans; Neoplasms; Rare Diseases; Research Design; Hematology; OncologyClinical trialsNeoplasmsReimbursementPriority journaleducation.field_of_studyClinical Studies as TopicClinical studies as topicHematologyRare diseasesEuropeOncologyResearch designResearch DesignClinical decision makingHumanmedicine.medical_specialtyPractice guidelineCase findingPopulationHealth care qualityReviewsCancer researchClinical studyRare DiseasesSDG 3 - Good Health and Well-beingConceptual frameworkmedicineHumansRare cancersTumor markerIntensive care medicineeducationAntineoplastic activityFlexibility (engineering)Surrogate endpointbusiness.industryMethodologyRare cancerStudy designCancer survivalReimbursementClinical trialClinical trials; Rare cancers; Research methodology; Hematology; OncologyPatient informationClinical effectivenessPosition paperNeoplasmbusinessRare disease
researchProduct

The role of heat shock proteins in neoplastic processes and the research on their importance in the diagnosis and treatment of cancer

2021

Heat shock proteins (HSPs) are chaperones with highly conservative primary structure, necessary in the processes of protein folding to the most energetically advantageous conformation and maintaining their stability. HSPs perform a number of important functions in various cellular processes and are capable of modulating pathophysiological conditions at the cellular and systemic levels. An example is the high level of HSP expression in neoplastic tissues, which disrupts the apoptosis of transformed cells and promotes the processes of proliferation, invasion, and metastasis. In addition, an increasing amount of information is appearing about the participation of HSPs in the formation of multi…

Review PaperResearch groupsbusiness.industryDisease progressionRapoptosisCancermedicine.diseaseanti-cancer therapy.Cancer treatmentMetastasisOncologyHeat shock proteinheat shock proteinsmedicineCancer researchMedicineNeoplastic ProcessescancerRadiology Nuclear Medicine and imagingProtein foldingbusinessanti-cancer therapyContemporary Oncology
researchProduct

Controversial issues in soft tissue solitary fibrous tumors: A pathological and molecular review

2019

The clinical evolution of solitary fibrous tumor (SFT) remains unclear. Although various clinical, morphological and molecular criteria may indicate increased risk of malignancy, some SFT can still progress despite having a clearly benign appearance. Various risk stratification systems have been proposed, but unfortunately they are not sufficient to precisely determine the malignant potential. In this review, we discuss current knowledge on SFT, focusing on the following controversial issues: (i) the diverse morphologic spectrum: 'the great simulator;' (ii) malignant transformation or dedifferentiation; (iii) current risk stratification systems; and (iv) molecular factors associated with cl…

Risk0301 basic medicinePathologymedicine.medical_specialtySolitary fibrous tumorMalignancyPathology and Forensic MedicineMalignant transformationDiagnosis Differential03 medical and health sciences0302 clinical medicinemedicineHumansPathologicalbusiness.industrySoft tissueGeneral MedicineCell DedifferentiationPrognosismedicine.diseaseImmunohistochemistryCell Transformation Neoplastic030104 developmental biologyIncreased riskSolitary Fibrous Tumors030220 oncology & carcinogenesisRisk stratificationbusinessPathology International
researchProduct

Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines.

2013

J. Balmana1, F. Balaguer2, A. Cervantes3 & D. Arnold4, on behalf of the ESMO Guidelines Working Group* Department of Medical Oncology, Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona; Department of Gastroenterology, Hospital Clinic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain; Department of Medical Oncology, Tumor Biology Clinic, Albert Ludwigs University, Freiburg, Germany;

Riskmedicine.medical_specialtyColorectal cancerChemopreventionDNA Mismatch RepairDNA GlycosylasesNeoplastic Syndromes Hereditaryhealth services administrationMedicineHumansGenetic Predisposition to DiseaseGenetic TestingMultiple PolypsSigmoidoscopyEarly Detection of CancerAgedTumor biologybusiness.industryBrain NeoplasmsGeneral surgeryHematologyColonoscopyFamilial riskMiddle Agedmedicine.diseaseColorectal Neoplasms Hereditary NonpolyposishumanitiesClinical PracticeEuropeOncologyAdenomatous Polyposis Colipopulation characteristicsFemaleMicrosatellite InstabilitybusinessColorectal NeoplasmsColorectal Surgerygeographic locationsAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Risk of scleroderma according to the type of immune checkpoint inhibitors

2020

Abstract Introduction Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs). Among them, ICIs-induced systemic sclerosis (SSc) is poorly known. Methods To better characterize this irAE, our comprehensive approach combined the description of ICIs-induced scleroderma cases, the systematic review of the literature and the analysis of VigiBase, the WHO pharmacovigilance database. Results We identified two cases with underlying limited cutaneous SSc who presented a dramatic increase in the skin thickening following pembrolizumab, associated with scleroderma renal crisis in one case. In the literature, four cases of scleroderma and four cases of morphea hav…

Riskmedicine.medical_specialtyScleroderma SystemicDurvalumabintegumentary systembusiness.industryImmunologyScleroderma Renal CrisisIpilimumabPembrolizumabmedicine.diseaseDermatologySclerodermaAntineoplastic Agents ImmunologicalAtezolizumabNeoplasmsmedicineHumansImmunology and AllergyNivolumabskin and connective tissue diseasesbusinessMorpheamedicine.drugAutoimmunity Reviews
researchProduct

Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

2016

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This pa…

Riskmedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentHematopoietic stem cell transplantationNeutropeniaSettore MED/17 - MALATTIE INFETTIVEHematopoietic stem cell transplantation; Leukemia; Molds; Risk factors; Yeast; Antineoplastic Combined Chemotherapy Protocols; Disease Susceptibility; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive Fungal Infections; Risk; Hematology; OncologyHematopoietic stem cell transplantation; Leukemia; Molds; Risk factors; Yeast; Hematology; OncologyMolds03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientAspergillusHematologyLeukemiabiologyIncidence (epidemiology)IncidenceHematopoietic Stem Cell TransplantationHematologyhematopoietic stem cell transplantation; Leukemia; Molds; Risk factors; Yeastmedicine.diseasebiology.organism_classificationYeastSettore MED/15 - MALATTIE DEL SANGUELeukemiaOncologyRisk factorsMold030220 oncology & carcinogenesisHematologic NeoplasmsRisk stratificationImmunologyhematopoietic stem cell transplantationRisk factorDisease SusceptibilityInvasive Fungal Infections030215 immunology
researchProduct

Synthesis, computational docking and biological evaluation of celastrol derivatives as dual inhibitors of SERCA and P-glycoprotein in cancer therapy.

2021

Abstract A series of eleven celastrol derivatives was designed, synthesized, and evaluated for their in vitro cytotoxic activities against six human cancer cell lines (A549, HepG2, HepAD38, PC3, DLD-1 Bax-Bak WT and DKO) and three human normal cells (LO2, BEAS-2B, CCD19Lu). To our knowledge, six derivatives were the first example of dipeptide celastrol derivatives. Among them, compound 3 was the most promising derivative, as it exhibited a remarkable anti-proliferative activity and improved selectivity in liver cancer HepAD38 versus human normal hepatocytes, LO2. Compound 6 showed higher selectivity in liver cancer cells against human normal lung fibroblasts, CCD19Lu cell line. The Ca2+ mob…

SERCAAntineoplastic AgentsApoptosisPharmacologySarcoplasmic Reticulum Calcium-Transporting ATPaseschemistry.chemical_compoundStructure-Activity RelationshipCell Line TumorDrug DiscoverymedicineCytotoxic T cellHumansATP Binding Cassette Transporter Subfamily B Member 1P-glycoproteinCell ProliferationPharmacologyBinding SitesbiologyOrganic ChemistryCancerGeneral Medicinemedicine.diseaseMolecular Docking SimulationchemistryApoptosisDocking (molecular)CelastrolCell cultureDrug Resistance NeoplasmDrug Designbiology.proteinDrug Screening Assays AntitumorPentacyclic TriterpenesEuropean journal of medicinal chemistry
researchProduct

Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.

2015

Hepatocellular carcinoma is a challenging malignancy of global importance. It is the sixth most common solid malignancy and the third leading cause of cancer-related death, worldwide. Curative treatments at early stages include liver transplantation, resection and percutaneous ablation, while transarterial chemoembolization can improve survival in patients with intermediate tumor stage. Patients with mild, related symptoms and/or macrovascular invasion or extrahepatic spread are classified under the advanced stage. The standard of care in this group is sorafenib, an inhibitor of Raf kinase and vascular endothelial growth factor receptor, whose effectiveness has been proven by 2 recent rando…

SHARPOncologyHepatocellular carcinomamedicine.medical_treatmentOLTLiver transplantationGastroenterologyLiver cirrhosilaw.inventionAntineoplastic AgentRandomized controlled triallawPractice Patterns Physicians'Randomized Controlled Trials as TopicNexavarMedicine (all)Liver NeoplasmsGastroenterologyGeneral MedicineSorafenibLocoregional therapiePercutaneous ethanol injectionLiver NeoplasmRaf kinaseHepatocellular carcinomaLiver cancerLiver cancerHumanmedicine.drugSorafenibNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularAntineoplastic AgentsMalignancyTransarterial chemoembolizationInternal medicinemedicineCarcinomaChemotherapyHumansChemoembolization Therapeuticbusiness.industryPhenylurea CompoundsRadiofrequency ablationResectionmedicine.diseaseBCLCPercutaneous ethanol injectionbusinessDigestive diseases (Basel, Switzerland)
researchProduct